Literature DB >> 24704276

Differential expression of ARID3B in normal adult tissue and carcinomas.

Serene J Samyesudhas1, Lynn Roy2, Karen D Cowden Dahl3.   

Abstract

ARID3B is a DNA binding protein that is overexpressed in neuroblastoma and ovarian cancer. To understand the extent that ARID3B participates in tumor development, we assessed protein expression of ARID3B in normal adult and malignant tissues. We found that ARID3B is highly expressed in differentiated layers of squamous epithelium. We also examined expression of an alternative splice form of ARID3B and found that it has similar but not identical expression patterns to the full length ARID3B isoform. ARID3B has two closely related paralogues, ARID3A and ARID3C. Each of these 3 family members exhibits different patterns of expression. Of the ARID3 family members, ARID3B is the most widely expressed and is particularly expressed in epithelium. In addition to examining normal tissue, we investigated ARID3B expression in a variety of tumor types. Most notably we found that ARID3B expression is decreased in esophagus and stomach tumors compared to normal corresponding tissues. Our results indicate that the different patterns of ARID3B in normal tissues translate into different roles for ARID3B in carcinomas.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ARID3B; Differentiation; Immunohistochemistry; Stratified epithelium; Transcription factor

Mesh:

Substances:

Year:  2014        PMID: 24704276     DOI: 10.1016/j.gene.2014.04.007

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  9 in total

1.  ARID3B expression in primary breast cancers and breast cancer-derived cell lines.

Authors:  Ayse Selcen Oguz Erdogan; Nihan Ozdemirler; Merve Oyken; Murat Alper; Ayse Elif Erson-Bensan
Journal:  Cell Oncol (Dordr)       Date:  2014-08-14       Impact factor: 6.730

Review 2.  MicroRNAs and Corresponding Targets in Esophageal Cancer as Shown In Vitro and In Vivo in Preclinical Models.

Authors:  Ulrich H Weidle; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

3.  A miRNAs catalogue from third-stage larvae and extracellular vesicles of Anisakis pegreffii provides new clues for host-parasite interplay.

Authors:  S Cavallero; I Bellini; A Pizzarelli; B Arcà; S D'Amelio
Journal:  Sci Rep       Date:  2022-06-11       Impact factor: 4.996

4.  ARID3A and ARID3B induce stem promoting pathways in ovarian cancer cells.

Authors:  Paige Dausinas; Kirthi Pulakanti; Sridhar Rao; Jennifer M Cole; Richard Dahl; Karen D Cowden Dahl
Journal:  Gene       Date:  2020-02-13       Impact factor: 3.688

5.  Identification of Tumor Microenvironment-Related Prognostic Biomarkers for Ovarian Serous Cancer 3-Year Mortality Using Targeted Maximum Likelihood Estimation: A TCGA Data Mining Study.

Authors:  Lu Wang; Xiaoru Sun; Chuandi Jin; Yue Fan; Fuzhong Xue
Journal:  Front Genet       Date:  2021-06-03       Impact factor: 4.599

Review 6.  Do short, frequent DNA sequence motifs mould the epigenome?

Authors:  Timo Quante; Adrian Bird
Journal:  Nat Rev Mol Cell Biol       Date:  2016-02-03       Impact factor: 94.444

7.  ARID3B Directly Regulates Ovarian Cancer Promoting Genes.

Authors:  Alexander Bobbs; Katrina Gellerman; William Morgan Hallas; Stancy Joseph; Chao Yang; Jeffrey Kurkewich; Karen D Cowden Dahl
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

8.  Identification of the key transcription factors in esophageal squamous cell carcinoma.

Authors:  Yuefeng Zhang; Yanzhao Xu; Zhenhua Li; Yonggang Zhu; Shiwang Wen; Mingbo Wang; Huilai Lv; Fan Zhang; Ziqiang Tian
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

9.  ARID3B: a Novel Regulator of the Kaposi's Sarcoma-Associated Herpesvirus Lytic Cycle.

Authors:  Jennifer J Wood; James R Boyne; Christina Paulus; Brian R Jackson; Michael M Nevels; Adrian Whitehouse; David J Hughes
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.